Callan Family Office LLC Makes New Investment in STERIS plc $STE

Callan Family Office LLC purchased a new position in STERIS plc (NYSE:STE - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 1,836 shares of the medical equipment provider's stock, valued at approximately $441,000.

Other institutional investors also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its position in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock worth $29,000 after buying an additional 104 shares during the period. Grove Bank & Trust increased its position in STERIS by 4,733.3% in the 1st quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider's stock worth $33,000 after buying an additional 142 shares during the period. Zions Bancorporation National Association UT bought a new position in STERIS in the 1st quarter worth approximately $37,000. ORG Wealth Partners LLC bought a new position in STERIS in the 1st quarter worth approximately $43,000. Finally, Golden State Wealth Management LLC increased its position in STERIS by 503.0% in the 1st quarter. Golden State Wealth Management LLC now owns 199 shares of the medical equipment provider's stock worth $45,000 after buying an additional 166 shares during the period. 94.69% of the stock is owned by institutional investors.

STERIS Price Performance

Shares of STE stock opened at $237.92 on Wednesday. The stock's fifty day simple moving average is $244.75 and its 200 day simple moving average is $236.07. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. The firm has a market cap of $23.43 billion, a price-to-earnings ratio of 36.43 and a beta of 1.01. STERIS plc has a one year low of $200.98 and a one year high of $253.00.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 EPS for the quarter, beating the consensus estimate of $2.32 by $0.02. The business had revenue of $1.40 billion for the quarter, compared to analyst estimates of $1.36 billion. STERIS had a return on equity of 14.17% and a net margin of 11.61%.STERIS's quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.03 EPS. On average, analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 26th. Investors of record on Thursday, September 4th were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, September 4th. This represents a $2.52 annualized dividend and a yield of 1.1%. This is a positive change from STERIS's previous quarterly dividend of $0.57. STERIS's payout ratio is presently 38.59%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on STE. Weiss Ratings restated a "buy (b)" rating on shares of STERIS in a research report on Tuesday. KeyCorp boosted their price objective on STERIS from $277.00 to $288.00 and gave the company an "overweight" rating in a research report on Tuesday, July 22nd. Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 14th. Finally, Morgan Stanley boosted their price objective on STERIS from $276.00 to $295.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $273.50.

Insider Buying and Selling

In other STERIS news, Director Mohsen Sohi sold 4,110 shares of the business's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $241.96, for a total value of $994,455.60. Following the transaction, the director owned 22,361 shares of the company's stock, valued at approximately $5,410,467.56. The trade was a 15.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel A. Carestio sold 159 shares of the business's stock in a transaction on Monday, October 6th. The stock was sold at an average price of $241.82, for a total value of $38,449.38. Following the completion of the transaction, the chief executive officer directly owned 51,096 shares in the company, valued at approximately $12,356,034.72. This represents a 0.31% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,868 shares of company stock valued at $4,585,389. Insiders own 1.07% of the company's stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.